SF

Shinichiro Fuse

Managing Director at TPG

Cambridge, Massachusetts

Overview

Work Experience

  • Partner/Managing Director

    2021 - Current

    Partner/Co-Lead, Life Sciences Innovations (LSI) Fund. Investments: Santa Ana Bio (Board), Sudo Biosciences (Board).

  • Board Member

    2020 - 2021

  • Interim CEO / Board Member

    2019 - 2020

    Circular RNA newco, MIT spinout (fka Oroboros)

  • Advisor

    2019 - 2021

    Board observer

  • Founding/Interim Senior Vice President, Business Development

    2017 - 2019

    Led BD for ElevateBio (MPM newco) from launch - BD strategy, deal sourcing, diligence, transactions, establishment of Elevate subsidiaries, alliance management. Launched newcos/deals include AlloVir (fka Viracyte), HighPassBio, and other stealth newco's. Supported initial LifeEdit negotiations.

  • Managing Director

    2018 - 2021

    Life science venture capital & newco building. Investments: Orna (board + interim CEO), Triplet Therapeutics (board), ElevateBio (board observer), AlloVir (NASDAQ: ALVR), Repare Therapeutics (RPTX, board observer til IPO), CODA Biotherapeutics (board observer), iTeos Therapeutics (ITOS), 28-7, iOmx Therapeutics (board, starting 06/2020-), Crossbow

  • Principal

    2016 - 2018

  • Director, Business Development

    2015 - 2016

    Deal sourcing, diligence, negotiations, alliance management, strategy, and competitive intelligence. Lead/support on academic/corporate licenses/options, sponsored research, and M&A (Pregenen).

  • Senior Manager, Business Development

    2014 - 2015

  • Engagement Manager

    2013 - 2014

    Corporate Development team: Business development, corporate strategy, valuation, revenue forecasting, launch planning, indication prioritization.

  • Senior Consultant

    2012 - 2013

  • Associate

    2011 - 2012

    Founding & operational team of Vedanta Biosciences (microbiome) and Mandara Sciences (nutrition). Technology sourcing, due diligence, deal support, and newco building.

  • Consultant

    2009 - 2011

    Healthcare strategy consulting, primarily in oncology and immunology. Business development, corporate strategy, revenue forecasting, sales operations, launch planning.

  • Associate Consultant

    2008 - 2009

  • Summer Associate

    2007 - 2007

    Institutional Equities Division (Equity Research, Equity Sales & Trading). Industry and company analysis.

Relevant Websites